This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Russo, A. Articles by Bazan, V. Search for Related Content PubMed PubMed Citation Articles by Russo, A. Articles by Bazan, V.

p53 Mutations in L3-Loop Zinc-binding Domain, DNA-Ploidy, and S Phase Fraction Are Independent Prognostic Indicators in Colorectal Cancer

A Prospective Study with a Five-Year Follow-Up¹

Sections of Molecular Oncology [A. R., M. M., I. Z., V. B.], Surgical Oncology [M. A. L., N. G., G. P.], and Medical Oncology [M. R. V., S. S., N. G.], Department of Oncology, Regional Reference Center for the Biomolecular Characterization of Neoplasms and Genetic Screening of Hereditary Tumors, Institute of Pathology [R. M. T.], and Biomolecular Section, Department of Cellular and Development Biology [I. A., M. L. F.], University of Palermo, and Epidemiological Observatory Center of Sicilian Region [G. D.], Palermo, Italy 90144

p53 gene alterations are among the most common events observed in colorectal cancer,and are accompanied frequently by DNAaneuploidy and high proliferative activity. The prognosticsignificance of such mutations remains controversial. We prospectively evaluated the prognostic significance of p53 mutations, DNA-ploidy, and S phase fraction (SPF) in a consecutive series of 160 colorectal cancer patients (median follow-up 71 months). Tumor DNA was screened for p53 mutations by PCR/single-strand conformational polymorphism/sequencing. DNA-ploidy and SPF were assessed by DNA flow cytometry. p53 mutations were detected in 68 of 160 (42.5%) cases. In 56% (38 of 68) of these, p53 mutations were found in conserved areas of the gene and in 44% (30 of 68 cases) outside the conserved regions. Eighteen of the 68 cases (26%) had mutations in the L3 loop, 11 of 68 (16%) in the L1 loop-sheet- helix motif, and 39 of 68 (58%) outside L3 and loop-sheet- helix. Seventy-five percent of the cases (120 of 160) showed DNA aneuploidy, whereas 18% of these (22 of 120) were multiclonal. The major independent predictors for both disease relapse and death were advanced Dukes’ stage, p53 mutations affecting L3 loop, DNA-aneuploid tumors, and high SPF (>18.5%). Our results show that mutations in L3 functional domain, more than any mutations, are important biological indicators to predict the outcome of patients indicating that these mutations have biological relevance in terms of colorectal cancer disease course.

This article has been cited by other articles:

				A Walther, R Houlston, and I Tomlinson Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis Gut, July 1, 2008; 57(7): 941 - 950. [Abstract] [Full Text] [PDF]

				G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327. [Abstract] [Full Text] [PDF]

				B. Iacopetta, A. Russo, V. Bazan, G. Dardanoni, N. Gebbia, T. Soussi, D. Kerr, H. Elsaleh, R. Soong, D. Kandioler, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study Ann. Onc., May 1, 2006; 17(5): 842 - 847. [Abstract] [Full Text] [PDF]

				A. Russo, V. Bazan, B. Iacopetta, D. Kerr, T. Soussi, N. Gebbia, and for the TP53-CRC Collaborative Study Group The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment J. Clin. Oncol., October 20, 2005; 23(30): 7518 - 7528. [Abstract] [Full Text] [PDF]

				A B Hassan and C Paraskeva Colorectal cancer prognosis: is it all mutation, mutation, mutation? Gut, September 1, 2005; 54(9): 1209 - 1211. [Abstract] [Full Text] [PDF]

				J. P. Jakupciak, W. Wang, P. E. Barker, S. Srivastava, and D. H. Atha Analytical Validation of Telomerase Activity for Cancer Early Detection: TRAP/PCR-CE and hTERT mRNA Quantification Assay for High-Throughput Screening of Tumor Cells J. Mol. Diagn., August 1, 2004; 6(3): 157 - 165. [Abstract] [Full Text]